Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 9 of 9 citing Schwartz: Using a drug facts box to communicate drug benefits and harms: two randomized trials. (0.07 sec) 

Communicating Drug Benefits and Risks Effectively: There Must Be a Better Way


J Avorn, WH Shrank - Annals of Internal Medicine, 2009 - Am Coll Physicians
The information that patients receive about the drugs we prescribe for them is in a sorry
state. Patients are barraged by direct-to-consumer (DTC) advertising in virtually every medium
except cell phone ring-tones. In a health care system that rewards quantity over quality, ...
Cited by 2 - Related articles - All 4 versions

Health Care Reform 2009


U Coverage, C Effectiveness, P Plan, W Forums, V … - NY Times - healthcarereform.nejm.org
Since I began my current fight for health care reform 2 years ago, I have heard from hundreds
of Montanans from across the state. So many of them tell heartbreaking personal accounts of
tragedy and suffering that have resulted from our broken health care system. In nearly a ...
Related articles - Cached - All 4 versions

Editorial: Communicating Drug Benefits and Risks Effectively: There Must Be a …


AI Med - Ann Intern Med, 2009 - Am Coll Physicians
I read with a lot of interest the results of the US study showing that including drug facts boxes
in direct-to-consumer prescription drug advertising (DTCA) improved consumers' knowledge
of drug benefits and harms (1). Although this seems a laudable approach, I have several ...

Article: Using a Drug Facts Box to Communicate Drug Benefits and Harms: Two …


AI Med - Ann Intern Med, 2009 - Am Coll Physicians
To increase awareness of non-drug approaches to problems, the drug box includes a section
called "Other things to consider doing". The Amcid box suggests dietary changes like eating
smaller meals or avoiding alcohol before bedtime. We have not tested whether this ...

Bringing the FDA's Information to Market


S Woloshin, LM Schwartz - Archives of Internal Medicine, 2009 - archinte.highwire.org
Here is a challenge: Imagine you are asked to turn a new prescription drug into a
blockbuster. The drug is approved by the US Food and Drug Administration (FDA) to treat arthritis
pain. That is good news because the arthritis market is huge. But you face some big ...

Lost in Transmission--FDA Drug Information That Never Reaches Clinicians

- posterous.com [PDF] 
LM Schwartz, S Woloshin - New England Journal of Medicine, 2009 - content.nejm.org
Page 1. Perspective The NEW ENGLAND JOURNAL of MEDICINE october 29, 2009 n engl j
med 361;18 nejm.org october 29, 2009 1717 needed — to disseminate exist ing but practically
inaccessible information about the benefits and harms of prescription drugs. ...
Related articles - All 6 versions

Numbers Needed to Decide


S Woloshin, LM Schwartz - JNCI Journal of the National Cancer …, 2009 - jnci.oxfordjournals.org
Selling screening can be easy. Induce fear by exaggerating risk. Offer hope by exaggerating
the benefit of screening. And don't mention harms. It is especially easy with cancer—no diagnosis
is more dreaded. And we all the know the mantra: early detection is the best protection. ...
Related articles - All 3 versions

Cancer Care: A Microcosm of the Problems Facing All of Health Care


GP EXPECTATIONS - Am Coll Physicians
When is enough treatment really enough? This question often follows physicians in all areas
of med- icine and their patients throughout the course of treatment. The dilemma can be particularly
difficult for oncolo- gists for whom, giving an accurate prognosis is difficult. They tend to ...

[CITATION] GUIDING PATIENT EXPECTATIONS


BDON DATA
Related articles


 


Go to Google Home - About Google - About Google Scholar

©2009 Google